IL1B and cardiovascular disorder: Recently, although the inflammatory hypothesis of cardiovascular disease was demonstrated in 2 large-scale multicenter randomized clinical trials using either a selective IL-1β antagonist [141] or low-dose colchicine [142], its clinical application using other affordable mainstream anti-inflammatory therapies remains challenging [143].